What the study found
The report describes an 11-year-old boy with a rare FUS::TFCP2 fusion-positive rhabdomyosarcoma of the mandible. The authors report that surgery after ineffective chemotherapy was followed by 18 months of disease-free status.
Why the authors say this matters
The authors conclude that early pathological diagnosis and prompt surgical intervention are crucial for FUS::TFCP2 fusion-positive rhabdomyosarcoma because of its chemoresistance. They also note that optimal treatment strategies have not been established.
What the researchers tested
This is a case report of one pediatric patient with mandibular rhabdomyosarcoma and a FUS::TFCP2 fusion gene. The patient first received standard induction chemotherapy for rhabdomyosarcoma, and then underwent radical resection with segmental mandibulectomy and reconstruction using a rectus abdominis free flap.
What worked and what didn't
Standard induction chemotherapy was ineffective. Histological examination of the surgical specimen showed a viable tumor with minimal response to chemotherapy, while the patient remained disease-free for 18 months after surgery.
What to keep in mind
The report describes a single patient, so the findings are limited to one case. The abstract does not describe broader follow-up beyond 18 months or provide a comparative treatment study.
Key points
- The article reports a rare FUS::TFCP2 fusion-positive rhabdomyosarcoma in an 11-year-old boy.
- Standard induction chemotherapy for rhabdomyosarcoma was ineffective in this case.
- Radical surgery included segmental mandibulectomy and reconstruction with a rectus abdominis free flap.
- The surgical specimen showed a viable tumor with minimal response to chemotherapy.
- The patient remained disease-free for 18 months after surgery.
Disclosure
- Research title:
- Surgical resection controlled a chemoresistant pediatric mandibular rhabdomyosarcoma
- Authors:
- Kohtaro Eguchi, Eriko Uchida, Koichi Oshima, Kohei Fukuoka, Kayoko Tao, Ayumu Arakawa, Chihiro Fushimi, Go Omura, Taisuke Mori, Ai Yoshida, Katsuyoshi Koh, Seiichi Yoshimoto
- Institutions:
- National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, Saitama Children's Medical Center, Saitama Children's Medical Center, Saitama Children's Medical Center
- Publication date:
- 2026-03-09
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.